

Richard L Schilsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9323739/publications.pdf>

Version: 2024-02-01

170
papers

11,322
citations

57631

44
h-index

30010

103
g-index

172
all docs

172
docs citations

172
times ranked

15185
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. JCO Oncology Practice, 2022, 18, e426-e441.	1.4	16
2	Patient Experiences, Trust, and Preferences for Health Data Sharing. JCO Oncology Practice, 2022, 18, e339-e350.	1.4	2
3	Use of Biosimilar Medications in Oncology. JCO Oncology Practice, 2022, 18, 177-186.	1.4	15
4	Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology, 2022, 40, 106-106.	0.8	1
5	Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with high tumor mutational burden (hTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology, 2022, 40, 107-107.	0.8	5
6	Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study.. Journal of Clinical Oncology, 2022, 40, 3008-3008.	0.8	7
7	Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. Journal of Clinical Oncology, 2022, 40, 3114-3114.	0.8	2
8	Governance of a Learning Health Care System for Oncology: Patient Recommendations. JCO Oncology Practice, 2021, 17, e479-e489.	1.4	5
9	American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. Journal of Clinical Oncology, 2021, 39, 155-169.	0.8	65
10	The International Collaboration for Cancer Classification and Research. International Journal of Cancer, 2021, 148, 560-571.	2.3	32
11	Recommendations to Streamline and Standardize Clinical Trial Site Feasibility Assessments: An ASCO Research Statement. JCO Oncology Practice, 2021, 17, 41-51.	1.4	3
12	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCOâ€œFriends of Cancer Research Prior Therapies Work Group. Clinical Cancer Research, 2021, 27, 2408-2415.	3.2	14
13	Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCOâ€œFriends of Cancer Research Joint Research Statement. Clinical Cancer Research, 2021, 27, 2394-2399.	3.2	47
14	Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Nonâ€œSmall Cell Lung Cancer: Real-World Analysis of Select ASCO- <i>Friends</i> Recommendations. Clinical Cancer Research, 2021, 27, 2430-2434.	3.2	28
15	Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. Journal of Clinical Oncology, 2021, 39, 1165-1184.	0.8	54
16	Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. Npj Precision Oncology, 2021, 5, 33.	2.3	5
17	Pertuzumab plus trastuzumab (P+T) in patients (Pts) with uterine cancer (UC) with <i>ERBB2</i> or <i>ERBB3</i> amplification, overexpression or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology, 2021, 39, 5508-5508.	0.8	9
18	Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology, 2021, 39, 6043-6043.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Palbociclib (P) in patients (pts) with soft tissue sarcoma (STS) with CDK4 amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology, 2021, 39, 11565-11565.	0.8	6
20	Mortality risk for patients undergoing cancer treatment who acquire SARS-CoV-2: ASCO registry.. Journal of Clinical Oncology, 2021, 39, 6509-6509.	0.8	0
21	What can heart failure trialists learn from oncology trialists?. European Heart Journal, 2021, 42, 2373-2383.	1.0	9
22	â€˜Strategicâ€™ development of precision cancer medicine in the United States. Molecular Oncology, 2021, 15, 1747-1749.	2.1	3
23	Abstract CT173: Sunitinib (S) in patients (pts) with metastatic breast cancer (mBC) withFGFR1 mutations or amplifications: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. , 2021, , .		2
24	Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Journal of Clinical Oncology, 2021, 39, 2443-2451.	0.8	97
25	Talking the Talk About Tumor Genomic Testing. Journal of the National Cancer Institute, 2020, 112, 436-437.	3.0	1
26	Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. Oncologist, 2020, 25, e405-e411.	1.9	2
27	Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies. Journal of Clinical Oncology, 2020, 38, 480-487.	0.8	3
28	Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. JCO Global Oncology, 2020, 6, 1461-1471.	0.8	44
29	Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Targeted Oncology, 2020, 15, 743-750.	1.7	25
30	Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials. JAMA Network Open, 2020, 3, e2014661.	2.8	3
31	Closing the Rural Cancer Care Gap: Three Institutional Approaches. JCO Oncology Practice, 2020, 16, 422-430.	1.4	148
32	Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Targeted Oncology, 2020, 15, 733-741.	1.7	25
33	Progress in Cancer Research, Prevention, and Care. New England Journal of Medicine, 2020, 383, 897-900.	13.9	39
34	The National Clinical Trials Network and the cooperative groups: The road not taken. Cancer, 2020, 126, 5008-5013.	2.0	3
35	Patient Preferences Regarding Informed Consent Models for Participation in a Learning Health Care System for Oncology. JCO Oncology Practice, 2020, 16, e977-e990.	1.4	8
36	Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey. JCO Oncology Practice, 2020, 16, 417-421.	1.4	158

#	ARTICLE	IF	CITATIONS
37	Status Update on Data Required to Build a Learning Health System. <i>Journal of Clinical Oncology</i> , 2020, 38, 1602-1607.	0.8	18
38	Reply to M. Hutton-Potts and A.M. Joshua. <i>JCO Oncology Practice</i> , 2020, 16, 285-286.	1.4	0
39	Palbociclib in Patients With Non-“Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. <i>JCO Precision Oncology</i> , 2020, 4, 757-766.	1.5	52
40	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2020, 38, 1081.	0.8	101
41	Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4637-4637.	0.8	9
42	Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with <i>BRAF V600E</i> mutations: Results from the TAPUR Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 122-122.	0.8	10
43	Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with <i>ERBB2</i> amplification or overexpression: Results from the TAPUR Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 132-132.	0.8	38
44	Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 133-133.	0.8	28
45	Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5567-5567.	0.8	2
46	Biosimilar usage in practices within the ASCO PracticeNET learning network.. <i>Journal of Clinical Oncology</i> , 2020, 38, 77-77.	0.8	2
47	Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies. <i>Journal of Oncology Practice</i> , 2019, 15, 575-583.	2.5	7
48	Improving Cancer Diagnosis and Care: Patient Access to High-Quality Oncologic Pathology. <i>Oncologist</i> , 2019, 24, 1287-1290.	1.9	11
49	Effect of Public Deliberation on Patient Attitudes Regarding Consent and Data Use in a Learning Health Care System for Oncology. <i>Journal of Clinical Oncology</i> , 2019, 37, 3203-3211.	0.8	20
50	Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise. <i>Journal of Clinical Oncology</i> , 2019, 37, 1690-1694.	0.8	12
51	Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. <i>Nature Medicine</i> , 2019, 25, 751-758.	15.2	362
52	Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. <i>Journal of Clinical Oncology</i> , 2019, 37, 72-80.	0.8	17
53	Implementing Precision Medicine in Community-Based Oncology Programs: Three Models. <i>Journal of Oncology Practice</i> , 2019, 15, 325-329.	2.5	54
54	State of Cancer Care in America: Reflections on an Inaugural Year. <i>Journal of Oncology Practice</i> , 2019, 15, 163-165.	2.5	2

#	ARTICLE	IF	CITATIONS
55	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. <i>Journal of Clinical Oncology</i> , 2019, 37, 336-349.	0.8	101
56	Challenges and approaches to implementing master/basket trials in oncology. <i>Blood Advances</i> , 2019, 3, 2237-2243.	2.5	11
57	Palbociclib in Patients With Pancreatic and Biliary Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-8.	1.5	46
58	Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence Generation. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	1.5	7
59	Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1014-1014.	0.8	29
60	Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with <i>CDKN2A</i> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9041-9041.	0.8	7
61	Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA108-LBA108.	0.8	10
62	Hypertension and use of bevacizumab among patients treated in community settings.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18279-e18279.	0.8	0
63	Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6531-6531.	0.8	1
64	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1242-1253.	1.2	120
65	Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs?. <i>JAMA Oncology</i> , 2018, 4, 333.	3.4	10
66	The evidence framework for precision cancer medicine. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 183-192.	12.5	123
67	Hans Christian Andersen and the Value of New Cancer Treatments. <i>Journal of the National Cancer Institute</i> , 2018, 110, 441-442.	3.0	6
68	Reply to S.D. Lucio. <i>Journal of Clinical Oncology</i> , 2018, 36, 2127-2127.	0.8	0
69	A New Look at the State of Cancer Care in America. <i>Journal of Oncology Practice</i> , 2018, 14, 397-399.	2.5	3
70	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2018, 36, 1020-1044.	0.8	108
71	American Society of Clinical Oncology Statement: Biosimilars in Oncology. <i>Journal of Clinical Oncology</i> , 2018, 36, 1260-1265.	0.8	88
72	Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	1.5	98

#	ARTICLE	IF	CITATIONS
73	Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. <i>Journal of Clinical Oncology</i> , 2018, 36, 617-623.	0.8	18
74	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Journal of Clinical Oncology</i> , 2018, 36, 1631-1641.	0.8	668
75	The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey. <i>Journal of Oncology Practice</i> , 2018, 14, e412-e420.	2.5	114
76	Accelerating anticancer drug development – opportunities and trade-offs. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 777-786.	12.5	52
77	Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. , 2018, 6, 108.		16
78	Rationale, Opportunities, and Reality of Biosimilar Medications. <i>New England Journal of Medicine</i> , 2018, 378, 2036-2044.	13.9	56
79	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018, 100, 35-45.	1.3	29
80	Access versus evidence: The regulators’ dilemma. <i>Clinical Trials</i> , 2018, 15, 240-242.	0.7	4
81	Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with <i>CDKN2A</i> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2532-2532.	0.8	27
82	Association of RAS mutations with race in metastatic colorectal cancer: CALGB/SWOG 80405 (ALLIANCE).. <i>Journal of Clinical Oncology</i> , 2018, 36, 638-638.	0.8	3
83	Use of next-generation sequencing tests to guide cancer treatment: Results from a survey of U.S. oncologists.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6529-6529.	0.8	0
84	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 1341-1367.	0.8	318
85	Reply to L. Casadaban et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1373-1374.	0.8	0
86	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2392.	3.8	670
87	Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus. <i>Cell</i> , 2017, 171, 982-986.	13.5	13
88	Finding the Evidence in Real-World Evidence: Moving from Data to Information to Knowledge. <i>Journal of the American College of Surgeons</i> , 2017, 224, 1-7.	0.2	39
89	Reply to J.P. Jansen, A. Messori et al, and H.S.L. Jim et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1134-1134.	0.8	0
90	Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. <i>Journal of Clinical Oncology</i> , 2017, 35, 3737-3744.	0.8	331

#	ARTICLE	IF	CITATIONS
91	Converging on the Value of Value Frameworks. <i>Journal of Clinical Oncology</i> , 2017, 35, 2732-2734.	0.8	8
92	Neutropenia related hospitalization risk in lung cancer patients with chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18290-e18290.	0.8	1
93	Highlights from the 2016 WIN Symposium, 27â€“29 June 2016, Paris: personalised therapy beyond next-generation sequencing. <i>Ecancermedalscience</i> , 2016, 10, 669.	0.6	1
94	Creating a Learning Health Care System in Oncology. , 2016, , 3-21.		4
95	Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). <i>Journal of Clinical Oncology</i> , 2016, 34, 3047-3053.	0.8	51
96	Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3872-3879.	0.8	28
97	Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. <i>Journal of Clinical Oncology</i> , 2016, 34, 3992-3999.	0.8	87
98	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. <i>Journal of Clinical Oncology</i> , 2016, 34, 2925-2934.	0.8	538
99	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2016, 34, 987-1011.	0.8	141
100	Response. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw001.	3.0	0
101	Extended <i>RAS</i> Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Antiâ€“Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. <i>Journal of Clinical Oncology</i> , 2016, 34, 179-185.	0.8	225
102	Impact of precision medicine in refractory malignancies: A meta-analysis of 13,203 patients in phase I clinical trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11520-11520.	0.8	4
103	Impact of primary (1Â°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3504-3504.	0.8	249
104	Highlights from the 2015 WIN Symposium: novel targets, innovative agents, and advanced technologiesâ€“a WINning strategy?. <i>Ecancermedalscience</i> , 2015, 9, 564.	0.6	2
105	Using Big Data to Track Trends in Medical Practice. <i>Journal of Oncology Practice</i> , 2015, 11, 69-70.	2.5	1
106	Opportunities for Translational Epidemiology: The Important Role of Observational Studies to Advance Precision Oncology. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 484-489.	1.1	13
107	Moving from Evaluation to Value in Cancer Care. <i>Clinical Cancer Research</i> , 2015, 21, 947-949.	3.2	4
108	Integrating biomarkers in colorectal cancer trials in the West and China. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 553-560.	12.5	11

#	ARTICLE	IF	CITATIONS
109	Generalizability of Trial Results to Elderly Medicare Patients With Advanced Solid Tumors (Alliance) Tj ETQq1 1 0.784314 rgBTJ/Overlook	3.0	27
110	Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2015, 33, 786-809.	0.8	102
111	Circadian variation in plasma 5-fluorouracil concentrations during a 24-hour constant-rate infusion. BMC Cancer, 2015, 15, 69.	1.1	22
112	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. Journal of Clinical Oncology, 2015, 33, 2563-2577.	0.8	783
113	Leveraging Biospecimen Resources for Discovery or Validation of Markers for Early Cancer Detection. Journal of the National Cancer Institute, 2015, 107, .	3.0	20
114	Innovative clinical trials for development of personalized cancer medicine. Molecular Oncology, 2015, 9, 933-934.	2.1	4
115	Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. Journal of the National Cancer Institute, 2015, 107, djv253.	3.0	139
116	Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. Journal of Clinical Oncology, 2015, 33, 3817-3825.	0.8	393
117	Modernizing Eligibility Criteria for Molecularly Driven Trials. Journal of Clinical Oncology, 2015, 33, 2815-2820.	0.8	80
118	A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget, 2015, 6, 14139-14152.	0.8	22
119	Personalized therapy in diverse cancers: Meta-analysis of 32,149 patients in phase II clinical trials.. Journal of Clinical Oncology, 2015, 33, 11097-11097.	0.8	0
120	Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405.. Journal of Clinical Oncology, 2015, 33, 3585-3585.	0.8	0
121	Therapeutic Interventional Mapping System (TIMS): A novel strategy for the selection of tri-targeted therapy combinations for non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 7524-7524.	0.8	0
122	Precision Cancer Medicine: The Future Is Now, Only Better. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 61-69.	1.8	38
123	Reply to F.E. Vera-Badillo et al. Journal of Clinical Oncology, 2014, 32, 3198-3198.	0.8	0
124	Building a Rapid Learning Health Care System for Oncology: The Regulatory Framework of CancerLinQ. Journal of Clinical Oncology, 2014, 32, 2373-2379.	0.8	97
125	Reply to L.K. Griffeth et al and J.E. Battley et al. Journal of Clinical Oncology, 2014, 32, 2812-2813.	0.8	0
126	Implementing personalized cancer care. Nature Reviews Clinical Oncology, 2014, 11, 432-438.	12.5	78

#	ARTICLE	IF	CITATIONS
127	Recommendations for management of patients with neuroendocrine liver metastases. <i>Lancet Oncology</i> , The, 2014, 15, e8-e21.	5.1	413
128	Wither the Cooperative Groups?. <i>Journal of Clinical Oncology</i> , 2014, 32, 251-254.	0.8	8
129	Progress Against GI Cancer During the American Society of Clinical Oncology's First 50 Years. <i>Journal of Clinical Oncology</i> , 2014, 32, 1521-1530.	0.8	36
130	American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. <i>Journal of Clinical Oncology</i> , 2014, 32, 1277-1280.	0.8	354
131	CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA3-LBA3.	0.8	68
132	CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA3-LBA3.	0.8	178
133	Association between ColDx assay result and recurrence-free interval in stage II colon cancer patients on CALGB (Alliance) 9581.. <i>Journal of Clinical Oncology</i> , 2014, 32, 455-455.	0.8	4
134	Systematic review of a personalized strategy in cancer clinical trials leading to FDA approval.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11047-11047.	0.8	0
135	ASCO's initiative to define value in cancer care. <i>American Journal of Managed Care</i> , 2014, 20, E1.	0.8	0
136	ecancermedalscience. <i>Ecancermedalscience</i> , 2013, 7, 344.	0.6	0
137	Publicly Funded Clinical Trials and the Future of Cancer Care. <i>Oncologist</i> , 2013, 18, 232-238.	1.9	20
138	Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581. <i>Journal of Clinical Oncology</i> , 2013, 31, 1775-1781.	0.8	163
139	Developing a virtual collaborative to facilitate palliative care and quality improvement learning in oncology.. <i>Journal of Clinical Oncology</i> , 2013, 31, 252-252.	0.8	1
140	A genotype-directed study to optimize dosing of irinotecan according to the UGT1A1 genotype.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2570-2570.	0.8	0
141	Lessons learned from the development of the CancerLinQ prototype: Clinical decision support.. <i>Journal of Clinical Oncology</i> , 2013, 31, 237-237.	0.8	2
142	Randomized Controlled Trials and Comparative Effectiveness Research. <i>Journal of Clinical Oncology</i> , 2012, 30, 4194-4201.	0.8	32
143	Development and Use of Integral Assays in Clinical Trials. <i>Clinical Cancer Research</i> , 2012, 18, 1540-1546.	3.2	35
144	Scarcity of vital oncology drugs: finding long-term solutions. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 597-9.	0.3	0

#	ARTICLE	IF	CITATIONS
145	Targeted therapy for cancer: asking the right questions. <i>Oncology</i> , 2012, 26, 947-9.	0.4	0
146	Advanced clinical trials for China. <i>Chinese Clinical Oncology</i> , 2012, 1, 3.	0.4	0
147	Update in Hematology and Oncology: Evidence Published in 2010. <i>Annals of Internal Medicine</i> , 2011, 154, 487.	2.0	0
148	Accrual to Cancer Clinical Trials in the Era of Molecular Medicine. <i>Science Translational Medicine</i> , 2011, 3, 75cm9.	5.8	18
149	Drug approval challenges in the age of personalized cancer treatment. <i>Personalized Medicine</i> , 2011, 8, 633-640.	0.8	4
150	Commentary: Tackling the Challenges of Developing Targeted Therapies for Cancer. <i>Oncologist</i> , 2010, 15, 484-487.	1.9	15
151	Personalizing Cancer Care: American Society of Clinical Oncology Presidential Address 2009. <i>Journal of Clinical Oncology</i> , 2009, 27, 3725-3730.	0.8	33
152	How not to treat cancer. <i>Lancet Oncology</i> , The, 2008, 9, 504-505.	5.1	3
153	Phase I and II clinical trial design for targeted agents. <i>Targeted Oncology</i> , 2006, 1, 220-227.	1.7	2
154	A Concise History of the Cancer and Leukemia Group B: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 3553s-3555s.	3.2	24
155	Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of Cancer and Leukemia Group B. <i>Journal of Clinical Oncology</i> , 2006, 24, 4553-4557.	0.8	73
156	Prospective, Randomized Comparison of High-Dose Chemotherapy With Stem-Cell Support Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Women With High-Risk Primary Breast Cancer: A Report of CALGB 9082, SWOG 9114, and NCIC MA-13. <i>Journal of Clinical Oncology</i> , 2005, 23, 2191-2200.	0.8	98
157	Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. <i>Journal of Clinical Oncology</i> , 2003, 21, 1431-1439.	0.8	1,464
158	Dose-Escalating Study of Capecitabine Plus Gemcitabine Combination Therapy in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 582-587.	0.8	47
159	End points in cancer clinical trials and the drug approval process. <i>Clinical Cancer Research</i> , 2002, 8, 935-8.	3.2	18
160	Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. <i>Investigational New Drugs</i> , 1999, 17, 97-101.	1.2	30
161	Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 84-87.	1.1	23
162	Methotrexate: An Effective Agent for Treating Cancer and Building Careers. <i>The Polyglutamate Era. Stem Cells</i> , 1996, 14, 29-32.	1.4	12

#	ARTICLE	IF	CITATIONS
163	Methotrexate: An Effective Agent for Treating Cancer and Building Careers. The Polyglutamate Era. <i>Oncologist</i> , 1996, 1, 244-247.	1.9	5
164	Prognostic factors for survival in patients treated in phase I clinical trials. <i>Cancer</i> , 1994, 74, 1965-1973.	2.0	58
165	Sequential therapy with dacarbazine and carmustine: a phase I study. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 509-514.	1.1	9
166	Modulation of vinblastine resistance with cyclosporine: A phase I study. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 54, 421-429.	2.3	40
167	Clinical cardiotoxicity of esorubicin (4?-deoxydoxorubicin,DxDx): Prospective studies with serial gated heart scans and reports of selected cases. <i>Investigational New Drugs</i> , 1990, 8, 221-6.	1.2	5
168	Clinical Pharmacokinetics of High-Dose Leucovorin Calcium After Intravenous and Oral Administration. <i>Journal of the National Cancer Institute</i> , 1990, 82, 1411-1415.	3.0	40
169	A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. <i>Cancer</i> , 1989, 63, 30-36.	2.0	42
170	Concomitant Hydroxyurea, 5â€Fluorouracil, and Radiation Therapy for Recurrent Head and Neck Cancer: Early Results. <i>Otolaryngology - Head and Neck Surgery</i> , 1988, 98, 295-298.	1.1	11